Main Menu

Western Coalition IDG Centers

Science is like real estate – location, location, location. At UCSF and Gladstone Institute a number of different IDG Consortium groups are represented, namely: Dr. M. McManus, Dr. S. Finkbeiner, Dr. B. Shoichet, and Dr. D. Kokel. The technologies represented by them span from CRISPR-Cas approach applied to mammalian cells, to longitudinal tracking of human neuron by variety of fluorescent tags or reporters, to modeling in vivo phenotyping via zebrafish, to computational compound docking screens. These groups have leveraged their proximity by sharing recent developments and challenges and furthered the illumination of a number different Druggable Genome.


TID Group (KMC)

A classification scheme for illumination of the Druggable Genome was developed by the UNM-KMC group by coalescing disparate and varied data sources of knowledge, resulting in grouping of target proteins as Tdark, Tchem, Tbio or Tclin. In this current phase of IDG funding, these classifications have been applied to the four protein superfamilies; Kinase, GPCR, Ion Channel and Nuclear Hormone Receptor. Further prioritization of what understudied protein should be studied can be challenging simply due to their classification of Tdark or understudied – thus having little knowledge. The TID group has developed a number of different resource tools for assessing Target Importance and Novelty, de-orphanization of orphan receptors, and shared these different priority lists among the different technology centers of the IDG Consortium as well to the KnockOut Mouse Project (KOMP2).


IDG Consortium

NIH established the Illuminating Druggable Genome (IDG) Consortium building a network of Knowledge Management Centers that collect and integrate data from across various resources to aid in prioritizing illumination of understudied protein targets and connecting these with Technology Development Centers that have brought forth new technologies and tool sets to shed light on to these targets.



Generation of experimental screening data measuring a variety of biological functions, disease state, and perturbation effects have been made public, though still remain elusive to many experimental biologist in their need to form novel hypotheses. The ISMMS-KMC group has developed a number of different software tools for enriching the knowledge from these publicly available data sets (i.e., GEO2Enrichr and Enrichr). An additional tool,, aggregates data from 66 different online resources generating attribute tables and similarity networks comparing these different databases. Thereby harmonizing these varied data for forming functional regulator networks that aids in knowledge discovery and hypothesis generation. Heatmaps generated from Harmonizome are incorporated into PHAROS.

The Role of IDG Knowledge Management Centers (KMC)





T.I. Oprea / L.A. Sklar

KMC grant at UNM includes a Data Organizing Core (DOC) led by Dr. Tudor Oprea, with the participation of groups from NNFCPR, EMBL-EBI and University of Miami, and an Administrative Core (AC), headed by Dr. Larry Sklar, which provides support and coordination across entire IDG Consortium.

Learn About UNM.




A. Ma'ayan / J.T. Dudley

The KMC at ISMMS have Dr. Avi Ma’ayan and Dr. Joel Dudley as co-PI’s.  Work in Dr. Ma’ayan’s lab has resulted in a number of different tools that allows for data integration and organization for comparison of protein functionality and expression with the aid of graph-theory algorithms and machine-learning techniques.

Learn About ISMMS.




A. Simeonov / R. Guha

As a partner with the KMC, NCATS developing and implementing PHAROS as the User Interface Portal to access all the integrated data, metadata and annotation collected via Data Organization Cores at UNM and ISMMS. 

Learn About NCATS.


University of Miami

S.C. Schurer

Dr. Stephan Schurer’s team has development the Drug Target Ontology that provides a framework for queries across a variety of data sources.

Their work has also been expanded to disease ontology mapping.

Learn About Miami.




A. Hersey

EMBL-EBI have developed tools for automated extraction and expert curation of various medicinal chemistry data. A group lead by Dr. Anne Hersey have resulted in extraction of pertinent target-chemical pairs from patent literature and late-stage drug development, or clinical candidate literature.

Learn About EMBL.




S. Brunak/ L.J. Jensen

Work by Dr. Lars Juhl Jensen has resulted in improved text-mining technology that is applied to scientific literature for scoring how well studied each target protein may be and support target prioritization. This text-mining platform also helps provide tissue and disease associations for the targets.

Learn About NNFCPR.



March 2016

NEW! Mark Your Calendars for the IDG Consortium Face-to-Face Meeting March 22, 2016 at the Residence Inn by Marriott Downtown Bethesda.

More News.



March 2016

09 Mar 2016: Molecular Medicine Tri-Conference presented by Oleg Ursu "Illuminating the Druggable Genome Knowledge Management Center" Extra link to speaker agenda for the session Bioinformatics for Big Data.

More Events.

Technology Development Group (Tech Dev)

The objective of the Tech Dev is to establish transformative scalable technology platforms and streamlined experimental workflows incorporated with multiple robust assay and physiological perturbation protocols for large-scale functional studies of poorly characterized and/or un-annotated proteins encoded by the Druggable Genome.



UNC: G.L. Johnson (TechDev1)

Dr. Gary L. Johnson’s group, in collaboration with Dr. Shawn Gomez, have developed and applied the technologies of Multiplex Inhibitor Beads (MIB) to capture and Mass Spectrometry (MS) to identify kinases for assessing the activation and regulation of kinome in response to perturbants. These technologies are being applied to model cell line as well as Patient Derived xenographs.

Learn About UNC.




B.L. Roth / B. Shoichet (TechDev 2)

Collaborative work by Dr. Bryan Roth and Dr. Brian Shoichet focuses on illuminating the druggable GPCR-ome by two-pronged approach of empirical screening of drugs followed by computational screening against modeled structures of the GPCR to produced optimized lead compounds. Their work has led to discovery of molecule “ogerin” binding previously orphaned, GPR68.

Learn About UNC/UCSF.




J.J. Yeh / D. Kokel (Tech Dev 3)

Development of zebrafish as in vivo model system for evaluating phenotypic responses by mutation or manipulation of genes via application of CRISPR-CAS system is the main focus of Dr. Jing-Ruey Yeh and Dr. David Kokel. This high throughput comprehensive phenotyping will help identify illuminate understudied targets and potential candidate ligands.

Learn About MGH/UCSF.



M.T. McManus (Tech Dev 4)

Dr. Michael T. McManus’ work for IDG is applying the CRISPR-CAS technology to unlock the hidden kinome (and will expand to other IDG protein classes) allowing for measuring the connection between genes and pathways by the utility of gene expression, gene activation or gene edition. Goals are to validate these Tdark matter and additional screens for epistatis.

Learn About UCSF.



S. Tomita (Tech Dev 5)

Regulation of synaptic transmission is critical component to human health, and Dr. Susumu Tomita studies Ion Channel functionality that is at the heart of these neural circuitry. His lab focuses on characterizing ion channels by utilizing transmembrane ORF collections to express proteins, then screening for functional modulators of ionotropic neurotransmitter receptors.

Learn About Yale.




S. Finkbeiner (TechDev 6)

Advances in robotic microscopy have lead Dr. Steve Finkbeiner’s group to develop physical exams of the human neurons by longitudinal tracking of neuron signaling and differentiation with the application and development of different fluorescent tags and markers. Validation of a variety of biosensors and fluorescent signals for assays have been completed and is being applied for identification of functional responses on orphan GPCRs.

Learn About Gladstone.




J. Qin (TechDev 7)

The technology of Transcription Factor Response Element pull-down assay has been implemented by Dr. Jun Qin’s group to detect modification of signaling transcription factors. Current work aimed at revealing responses due to drug stimulation and continual work expands these into different cell lines for comparison. Future work will look at responses in liver, lung and gastric tumor samples.

Learn About Baylor.



March 2016

Novel Technique Uncovers "Dark" G-Protein Coupled Receptors: Implications for Drug Discovery

Learn About News/events.